Key Insights

Highlights

Success Rate

84% trial completion

Published Results

34 trials with published results (10%)

Research Maturity

147 completed trials (42% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.0%

28 terminated out of 349 trials

Success Rate

84.0%

-2.5% vs benchmark

Late-Stage Pipeline

8%

27 trials in Phase 3/4

Results Transparency

23%

34 of 147 completed with results

Key Signals

34 with results84% success28 terminated

Data Visualizations

Phase Distribution

245Total
Not Applicable (115)
Early P 1 (14)
P 1 (59)
P 2 (30)
P 3 (18)
P 4 (9)

Trial Status

Completed147
Recruiting70
Unknown42
Terminated28
Active Not Recruiting24
Not Yet Recruiting16

Trial Success Rate

84.0%

Benchmark: 86.5%

Based on 147 completed trials

Clinical Trials (349)

Showing 20 of 20 trials
NCT05588141Phase 1RecruitingPrimary

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

NCT05317858Phase 3RecruitingPrimary

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

NCT03122197Early Phase 1RecruitingPrimary

Study of Letrozole in Recurrent Gliomas

NCT05047913Early Phase 1Active Not RecruitingPrimary

Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR

NCT02693990Not ApplicableActive Not Recruiting

A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas

NCT03286335Not ApplicableRecruitingPrimary

Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy

NCT02800486Phase 2Recruiting

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT06810544Phase 1Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06496971Phase 3Recruiting

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NCT04446416Not ApplicableCompleted

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NCT06329570Phase 1Recruiting

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT07520370Not ApplicableNot Yet RecruitingPrimary

Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor

NCT02153957Phase 2CompletedPrimary

Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors

NCT05819008Recruiting

Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries

NCT06388733Phase 3Recruiting

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT05947045Not ApplicableRecruitingPrimary

Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors

NCT02851706Completed

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

NCT06630338Not Yet RecruitingPrimary

Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements

NCT06368310Not ApplicableRecruitingPrimary

FIH Clinical Investigation of Graphene Electrodes for Brain Mapping

NCT04266665Phase 4CompletedPrimary

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Scroll to load more

Research Network

Activity Timeline